FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study
The FDA rejected ivonescimab in its present form, issuing a Complete Response Letter for Summit Therapeutics’ NSCLC BLA. The agency said a PFS benefit without significant overall survival does not establish substantial evidence of effectiveness.
